Breakthrough New Drug Could Send Tiny Stock Soaring

Is This New Drug The End Of Arthritis? [American Death Angel Summit] July 21, 2023 [UNSUBSCRIBE]( Breakthrough New Drug Could Send Tiny Stock Soaring [Matt Insley] MATT INSLEY Reader, [Meet the tiny stock behind what I call the “Humira Killer”…]( Take a look: [Click here to learn more]( [Click here for details on the “Humira Killer”…]( As you may know, Humira is the best-selling drug in the world… In total, since 2002, AbbVie (the company behind Humira) has made over $200 billion in sales from the drug. And that’s because arthritis (which Humira treats) is one of the biggest and most common diseases in America… It affects 54 million people, or well over 20% of our country’s adult population. Yet as you’re about to see, despite its popularity, Humira has a number of huge shortcomings: It’s not effective in many cases… it has potentially dangerous side effects… and it requires regular injections. [This breakthrough new drug is being designed to solve all of those problems…]( - It’s demonstrated in pre-clinical trials to be 70% more effective than Humira… - It does so without being shown to cause any serious side effects… - And best of all, it doesn’t require any injections – the dosing is done orally. Conservatively speaking, if [this pre-clinical drug]( manages to capture even 1/10th of Humira’s market share, that’d be more than enough to send the tiny stock behind it soaring 20-fold. And it all begins with an upcoming announcement expected just days from now. That’s why I’m urging you to act right away… [Click here for details.]( Regards, [Matt Insley] Matt Insley Executive Publisher, Paradigm Press © 2023 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your American Death Angel Summit e-mail subscription and associated external offers sent from American Death Angel Summit, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. American Death Angel Summit is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your American Death Angel Summit subscription, you can ensure its arrival in your mailbox by [whitelisting American Death Angel Summit.](